Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2007 by Assaf-Harofeh Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Assaf-Harofeh Medical Center Identifier:
First received: July 6, 2007
Last updated: NA
Last verified: July 2007
History: No changes posted

Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy.

We decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.

Condition Intervention
Diabetic Nephropathy
Renal Protection
Drug: Rosiglitasone (retrospective observation)

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Time Perspective: Retrospective
Official Title: Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study

Resource links provided by NLM:

Further study details as provided by Assaf-Harofeh Medical Center:

Study Start Date: August 2007
Estimated Study Completion Date: December 2007
  Show Detailed Description


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Diagnosis of Diabetes Mellitus Type II
  2. Treatment With Oral hypoglycemics
  3. Availability of Baseline and follow up clinical data

Exclusion Criteria:

  1. Insulin Therapy at baseline
  2. Malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00497666

Contact: Leonid S Feldman +972-8-9779383 ext 9383

Clalit Health Cervices, Central District Not yet recruiting
Zerifin,, Israel, 70300
Contact: Leonid S Feldman    +972-8-9779383 ext 9383   
Sub-Investigator: Shlomo Vinker, MD         
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Principal Investigator: Leonid S Feldman Nephrology Division, Assaf Harofeh Medical Center, Zerifin,
Principal Investigator: Leonid S Feldman Assaf-Harofeh Medical Center
  More Information Identifier: NCT00497666     History of Changes
Other Study ID Numbers: 346147Rosi
Study First Received: July 6, 2007
Last Updated: July 6, 2007

Keywords provided by Assaf-Harofeh Medical Center:
Diabetic nephropathy
renal protection

Additional relevant MeSH terms:
Kidney Diseases
Diabetic Nephropathies
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on May 25, 2017